Research Article

Polymorphisms in the IFNγ, IL-10, and TGFβ Genes May Be Associated with HIV-1 Infection

Felipe Bonfim Freitas, Sandra Souza Lima, Rosimar Neris Martins Feitosa, Vânia Nakauth Azevedo, Marluisa de O. Guimarães Ishak, Ricardo Ishak, and Antonio Carlos R. Vallinoto

Laboratory of Virology, Biological Sciences Institute, Federal University of Pará, 66075-110 Belém, PA, Brazil

Correspondence should be addressed to Antonio Carlos R. Vallinoto; vallinoto@ufpa.br

Received 25 June 2014; Revised 22 December 2014; Accepted 22 December 2014

Academic Editor: Helge Frieling

Copyright © 2015 Felipe Bonfim Freitas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. This study investigated possible associations between the TNFα-308G/A, IFNγ+874A/T, IL-6-174C/G, IL-10-1082A/G, and TGFβ-509C/T polymorphisms with HIV-1 infection, in addition to correlation of the polymorphisms with clinical markers of AIDS progression, such as levels of CD4+/CD8+ T lymphocytes and plasma viral load.

Methods. A total of 216 individuals who were infected with HIV-1 and on antiretroviral therapy (ART) and 294 individuals from the uninfected control group were analyzed.

Results. All individuals evaluated were negative for total anti-HBc, anti-HCV, anti-T. pallidum, and anti-HTLV-1/2. The polymorphisms were identified by PCR-RFLP. Individuals presenting the IFN+874A allele as well as the AA genotype were more frequent in the HIV-1 infected group compared to the control group (P<0.05), in addition to having lower levels of CD4+ T lymphocytes. The CD8+ T lymphocytes count was significantly lower in individuals with the IL-10-1082 GG genotype. The TGFβ-509TT genotype was associated with higher plasma viral load.

Conclusions. The results suggest that the presence of the IFN+874A allele confers susceptibility to HIV-1 infection and a decrease in the number of CD4+ T lymphocytes. In addition, the genotype associated with high serum levels of TGFβ may be associated with an increase in plasma viral load.

1. Introduction

HIV-1 infection leads to a progressive decline in the number of peripheral CD4+ T lymphocytes, dysfunctions in thymic T cells, and changes in the number and function of antigen-presenting cells, such as dendritic cells and monocytes [1, 2]. Although most (70–80%) individuals infected with HIV develop AIDS after years of clinical latency, there is a large amount of variation in the process of pathogenesis in different patients, with or without therapeutic intervention [3]. This interindividual variability in susceptibility to the virus, progression from infection to AIDS, success of transmission, or even in response to antiviral therapy has been attributed to the genetic makeup of the virus, environmental factors, and the existence of genetic variability in multiple host genes [4]. Among these host genes are genes encoding cytokines [5–7]. These cytokines can be functionally classified into proinflammatory (TNFα, IL-1, IL-6, IFNγ, and IL-8) and anti-inflammatory (IL-4, IL-10, IL-13, IL-1ra, and TGFβ) types and are important mediators of the immune response that function by binding to specific receptors in response to various stimuli [8]. In the context of HIV-1, genetic cohort studies have shown associations of several single nucleotide polymorphisms (SNPs) with different rates of progression and variation in susceptibility to infection [9], which involves genes encoding molecules that participate in the adsorption process and viral penetration into the host cell (CCR5, CCR2, RANTES, and SDF1), in the regulation of the immune response (IL-10, TNFα, and MBL), and in the recognition of epitopes of viral antigens by CD4+ and CD8+ T lymphocytes. In addition, the genotype associated with high serum levels of TGFβ may be associated with an increase in plasma viral load.
but few reports have focused patients from the Amazon region of Brazil, where the people have a genetic background composed by the mix of three ethnic groups. Therefore, the present study aimed to evaluate the occurrence of a possible association of TNF-$\alpha$-$308G/A$, IFN-$\gamma$-$509C/T$, TGF-$\beta$-$509C/T$, IL-6-$509C/T$, IL-10-$509C/T$, and IL-10R-$509C/T$ in the Brazilian population.

## 2. Materials and Methods

### 2.1. Examined Populations

A total of 216 investigated subjects who were infected with HIV-1 (130 men and 86 women), with a mean age of 39 ± 10.98 years, and who underwent follow-up at the Reference Unit Specializing in Infectious and Parasitic Diseases (Unidade de Referência Especializada em Doenças Infecciosas e Parasitárias (URE-DIPE)) located in Belém, the capital of the state of Pará, Brazil, were assessed from 2008 to 2010. All seropositive patients were part of the National Network of CD4+ and CD8+ T Cell Count and Plasma Viral Load, which is managed by the Brazilian Ministry of Health, and were undergoing antiretroviral therapy (ART). The control group was comprised of 294 healthy individuals (191 men and 103 women) with a mean age of 29 ± 9.39 years. The individuals from both patient and control groups had similar ethnic origins and risk for HIV-1 infection and were residents in the northern part of the country and its influence on laboratory markers of AIDS progression (CD4+ T lymphocytes and plasma viral load).

### 2.2. Serology, Viral Load, and CD4+ and CD8+ T lymphocyte Counts

All individuals involved in the study were tested for the presence of total anti-HBc (BioMérieux, Lyon, France), anti-HCV, anti-T. pallidum, and anti-HTLV-1/2 (Ortho Clinical Diagnostics, New Jersey, USA) antibodies, and those who were positive for any of the markers were excluded. The viral load was quantified by branched DNA assay (bDNA) (Bayer Corporation, Massachusetts, USA), which has a minimum detection limit of 50 RNA copies/mL. CD4+ and CD8+ T lymphocyte counts were performed by flow cytometry (FacsCount, Becton and Dickinson, USA) using a FACSCaliburTM Reagents immunomonitoring kit according to the standard protocol recommended by the manufacturer.

### 2.3. Identification of Polymorphisms

DNA was extracted from mononuclear cells from whole peripheral blood using the Gentra Systems Puregene DNA isolation kit (Invitrogen, Minneapolis, USA). Amplification of fragments of the TNF-$\alpha$, IFN-$\gamma$, TGF-$\beta$, IL-6, and IL-10 genes was performed by polymerase chain reaction (PCR) followed by identification of polymorphisms using the restriction fragment length polymorphism analysis (RFLP) (Table 1). Subsequently, the amplified products were subjected to electrophoresis in 4% agarose gels containing 5 µL of SYBR Safe DNA gel stain (10 mg/mL) (Invitrogen, Minneapolis, USA).

### 2.4. Statistical Analysis

The distributions of allele and genotype frequencies for each polymorphism in the infected and control groups were estimated by direct counting and compared using the chi-square test or Fisher’s exact test in cases where the sample size for a given genotype was lower than 5. Hardy-Weinberg equilibrium was tested using the chi-square test. The associations between genotypes and markers of progression (CD4+, CD8+ T lymphocytes and viral load) were evaluated using the Mann-Whitney test. A 5% significance level ($P \leq 0.05$) was adopted in all statistical analyses using the software BioEstat 5.0 [11].

## Table 1: Restriction enzymes, primer sequences, annealing temperatures, and fragments generated during polymorphism identification.

| Polymorphisms (endonuclease) | Primers | Genome location | Hybridization temperature (°C) | Alleles and fragments (bp) |
|--------------------------------|---------|-----------------|-------------------------------|--------------------------|
| rs1800795 (Nla III)            | IL-6 F: 5'-AAAGGAAGTGTTGCTCTTCTTCT-3', IL-6 R: 5'-ATCTTTTGTGAGGGTTGAGG-3' | -174G/C (promoter) | 59 | C: 85, 84, G: 169 |
| rs1800896 (Mnl I)              | IL-10 F: 5'-TCTGAGAAGTCCTGATGTC-3', IL-10 R: 5'-CTCTCTCTTACCTCCATCTCC-3' | -1082A/G (promoter) | 60 | A: 125, 65, G: 93, 65, 32 |
| rs243056l (Hind III)           | INFg F: 5'-GATTTTATTCTTACCAAACAAAATCGAGGGAC-3', INFg R: 5'-GCAAAGGCCCCCACCACATGATAA-3' | +874T/A (first intron) | 53 | A: 176, T: 148, 28 |
| rs1800629 (Nco I)              | TNFa F: 5'-AGGCAATAGGTTTTGAGGGCCAT-3', TNFa R: 5'-TCCTCTCTTCTCCGATTCCG-3' | -308G/A (promoter) | 60 | A: 107, G: 87, 20 |
| rs1800469 (Dde I)              | TGFβ1 F: 5'-GGAGAGGCAATTCTTACAGGTG-3', TGFβ1 R: 5'-TAGGAGAGGAGGAGGCTC-3' | -509C/T (promoter) | 61 | T: 120, C: 74, 46 |

F: forward; R: reverse; bp: base pairs.
3. Results

3.1. Allelic and Genotypic Frequencies. An analysis of deviations between the observed and expected allele and genotype proportions in both groups revealed that both populations were in Hardy-Weinberg equilibrium ($P > 0.05$) for all polymorphisms studied.

In Table 2, it is shown that the allelic and genotypic distributions of the TNFα, IL-10, IL-6, and TGFβ genes did not differ significantly between the two population groups. However, for the IFNγ gene, allele A, which is associated with low serum levels of IFNγ, and the homozygous AA genotype were associated with HIV-1 infection ($P = 0.0172$ and $P = 0.0336$, resp.). The odds ratio (OR) showed that individuals carrying the AA genotype had a 1.5 times greater chance of being infected with HIV-1 ($P = 0.0198$), and the presence of the A allele was associated with a 1.3 times greater risk ($P = 0.0210$).

3.2. Association of Genotypes with Levels of CD4+ and CD8+ T lymphocytes. For this analysis, the mean values of the last three CD4+ and CD8+ T lymphocyte counts from each individual were used, which were accessed in the Control System for Laboratory Tests of the National Network of CD4+/CD8+ T Lymphocyte Count and Viral Load (Sistema de Controle de Exames Laboratoriais da Rede Nacional de Contagem de Linfócitos TCD4+/CD8+ e Carga Viral (SISCHEL)). The mean count values did not differ significantly between the genotypes of the IL-6, TNFα, IL-10, and TGFβ genes (Figures 1 and 2). However, carriers of the IFNγ TT genotype (Figure 1(a)) had significantly higher counts of CD4+ T lymphocytes (586 cells/mL) when compared to carriers of genotypes AA (473 cells/mL) and AT (424 cells/mL).

Individuals carrying the IFNγ TT genotype showed higher levels of CD8+ T lymphocytes (1,118 cells/mL) when compared to genotypes AA and AT (983 and 926 cells/mL, resp.), but without statistical significance. The individuals carrying the IL-10 AG (1,032 cells/mL) and AA (955 cells/mL) genotypes had significantly higher levels of CD8+ T lymphocytes compared to those with the IL-10 GG genotype (744 cells/mL) (Figure 2(d)).

3.3. Genotypes and Plasma Viral Load. Following the same pattern of analysis used for the levels of T lymphocytes, where mean of last 3 measurements from each individual was used, the viral load for the various genotypes was carried out to investigate whether there were differences between plasma viral load values and genotypes. Differences in the distribution of genotype frequencies by plasma viral load values were significantly different between genotypes of the TGFβ gene, and the TGFβ TT genotype was associated with higher viral load values (Figure 3(e)).

4. Discussion

The allelic and genotypic distributions of the genes evaluated in this study show variations that are characteristic of distinct ethnic groups, though a study performed by Kaur et al. [12] in northern India found frequencies similar to those observed in the present study for the IFNγ+874TT, TNFα-308A, IL-6-174C, IL-10-1082G, and TGFβ-509T alleles. However, other studies have found very distinct frequencies of the IL-6-174C allele in Australians [7], the IL-10-1082G allele in Spaniards [13] and Chinese [14], and the TNFα-308A allele in Africans [15]. These differences may be a reflection of different population models, criteria, methods, or sample sizes used in the studies. It is important to note that the genetic contribution of the Amazon population analyzed in this study was characterized using a trihybrid model, with 47% Caucasians, 41% indigenous people, and 12% African descendants [16], and differs from profiles analyzed in other studies, which were formed almost exclusively by single ethnic groups.

In North Americans infected by HIV-1 [17], the frequencies of the IL-10-1082G, IL-4-33T, and IL-2-166T alleles differed significantly only in individuals of African and Hispanic descent, suggesting that some polymorphisms may be indicative of susceptibility and progression of infection by the different population groups. Most genetic studies have been conducted in Caucasians [7, 18–21] and South African populations [15, 22–24]. In Brazil, an association of the TNFα-308A allele with susceptibility to HIV-1 infection was observed; however, unlike our study, this was done in the Southeast region of the country and analyzed individuals diagnosed with AIDS who had clinical manifestation of retinitis by CMV [25]; another study, also conducted in the same region, investigated polymorphisms in the genes of IL-18 and IFNγ in patients with lipodystrophy; however, no influence of the IFNγ-874A allele was found [26].

Some studies have indicated strong associations of the IFNγ-874A/T polymorphism in patients infected with HIV-1. It has been suggested that individuals with the homozygous IFNγ-874A/A genotype have a significantly higher risk of infection and progression to AIDS [27], similar to the results found here. Likewise in Korean individuals, a significantly higher frequency of the T allele, which is associated with the production of high levels of IFNγ, was found in the control group compared to the infected group [28]. Cases of multiple sclerosis in HIV-infected individuals were also associated with the AA genotype [29], suggesting that this genotype may influence the clinical deterioration of these infected individuals.

IFNγ is a cytokine produced by T and activated NK cells in response to pathogen invasion. The biological actions of this cytokine are diverse and include immunomodulatory effects, activation of macrophages, and antimicrobial and antiproliferative activities [30]. Binding of IFNγ to its receptor activates STAT-1, which in turn binds to transcription factors that will stimulate MHC-II, protein kinase (PKR), and ribonuclease L expression. Thus, blocking or failure of the IFNγ signaling pathway confers higher susceptibility to infections, suggesting that secretion of IFNγ may be an important effector function for the suppression of HIV-1 and other viral infections [31–33]. In this study, the IFNγ+874TT genotype, which is associated with high IFNγ production, was related to considerably higher levels of CD4+ T lymphocytes compared to the other two genotypes (AA and AT). Th1 lymphocytes secrete IL-2, IFNγ, and TNFα/β to direct an immune
Table 2: Distribution of allelic and genotypic frequencies in the genes of IFNγ, TNFα, IL-10, IL-6, and TGFβ cytokines in the groups studied.

| Genotypes and alleles | HIV-1 (%) N = 216 | Control (%) N = 294 | P^a | OR (95% CI) | P^b |
|-----------------------|-------------------|---------------------|-----|-------------|-----|
| **IFNγ**              |                   |                     |     |             |     |
| AA                    | 111 (51.39)       | 117 (39.79)         | 0.0336 | 1.5776 | 0.0198 |
| AT                    | 89 (41.20)        | 148 (50.35)         |       | (1.09–2.28)|     |
| TT                    | 16 (7.41)         | 29 (9.86)           |       |             |     |
| A                     | 311 (71)          | 382 (65)            | 0.0172 | 1.3860 | 0.0210 |
| T                     | 121 (29)          | 206 (35)            |       | (1.05–1.81)|     |
| **TNFα**              |                   |                     |     |             |     |
| AA                    | 4 (1.86)          | 6 (2.04)            | 0.9887 | 0.9922 | 0.9416 |
| AG                    | 42 (19.44)        | 57 (19.39)          |       | (0.25–3.26)|     |
| GG                    | 170 (78.70)       | 231 (78.57)         |       |             |     |
| A                     | 50 (12)           | 69 (12)             | 0.9372 | 0.9845 | 0.9843 |
| G                     | 382 (88)          | 519 (88)            |       | (0.66–1.45)|     |
| **IL-10**             |                   |                     |     |             |     |
| AA                    | 123 (56.94)       | 159 (54.09)         | 0.7645 | 1.3261 | 0.5368 |
| AG                    | 79 (36.58)        | 111 (37.75)         |       | (0.65–2.67)|     |
| GG                    | 14 (6.48)         | 24 (8.16)           |       |             |     |
| A                     | 325 (75)          | 429 (73)            | 0.4139 | 1.1257 | 0.4565 |
| G                     | 107 (25)          | 159 (27)            |       | (0.84–1.49)|     |
| **IL-6**              |                   |                     |     |             |     |
| GG                    | 142 (65.74)       | 184 (62.59)         | 0.1856 | 2.7011 | 0.1241 |
| GC                    | 70 (32.41)        | 96 (32.65)          |       | (0.87–8.38)|     |
| CC                    | 4 (1.85)          | 14 (4.76)           |       |             |     |
| G                     | 354 (82)          | 464 (79)            | 0.2288 | 1.2129 | 0.2621 |
| C                     | 78 (18)           | 124 (21)            |       | (0.88–1.66)|     |
| **TGFβ**              |                   |                     |     |             |     |
| TT                    | 43 (19.91)        | 59 (20.07)          | 0.2136 | 0.7959 | 0.4439 |
| TC                    | 97 (44.91)        | 152 (51.70)         |       | (0.48–1.31)|     |
| CC                    | 76 (35.18)        | 83 (28.23)          |       |             |     |
| T                     | 183 (42)          | 270 (46)            | 0.2587 | 0.8656 | 0.2864 |
| C                     | 249 (58)          | 318 (54)            |       | (0.67–1.11)|     |

P^a: analysis between the two groups (Fisher’s exact test or chi-square test). P^b: odds ratio.

response against intracellular pathogens and stimulate a predominantly cellular immune profile [34]. Additionally, IFNγ plays an important role in positive regulation of genes that encode MHC-I, subsequently increasing the potential for cytotoxic T lymphocytes to recognize foreign peptides and thereby promote the induction of cellular immunity [35, 36]. Therefore, high levels of IFNγ stimulate the clonal expansion of CD4+ T lymphocytes to promote the maintenance of a response during the course of HIV-1 infection.

The effects and mechanisms involving IL-10 action in the pathogenesis of HIV-1 are quite controversial, suggesting that factors associated with the host, virus, and study models used may lead to these results. Several studies show that alleles associated with low serum levels of IL-10 are linked to increased susceptibility to HIV-1 infection and accelerated progression to AIDS, particularly in later stages of the disease [6, 37, 38]. In contrast, other studies demonstrate a protective role of the alleles that are associated with low levels of IL-10 (-1082AA and -592A) [17, 23]. Naicker et al. demonstrated that these alleles conferred susceptibility to HIV infection. In acute infection, low levels could promote protective effects since high levels may promote viral replication by suppressing innate and adaptive immune responses, but in chronic infection stage, high levels of IL-10 may be protective by reducing immune activation and inhibiting HIV replication in macrophages [23]. In animal models, removal of the IL-10 gene or blocking of the activation pathway increases T cell responses, resulting in rapid elimination of the virus and in the development of a response by memory T cells, culminating in virus shedding [39, 40]. The present study found that genotypes associated with low levels of IL-10 (-1082AA and AG) were associated with higher CD8+ T lymphocyte counts compared to genotype -1082GG. Similar to our results, Naicker et al. [22] found that genotype -592AA (low levels) was associated with a greater magnitude of response from virus-specific CD8+ T lymphocytes, suggesting that allelic variants can influence the rate of disease progression by regulating serum levels.
and modulating the immune response by cytotoxic lymphocytes.

In this study, the TGFβ-509TT genotype, which is related to high production levels of TGFβ, was more frequent among individuals with higher plasma viral load levels, even though all patients were undergoing an ART regimen. It is known that TGFβ stimulates the expression of CTLA-4, inhibiting IL-2 production [41]. The frequency of Treg cells that are positive for CTLA-4 is enhanced in patients with chronic infection with HIV-1, leading to an immune dysfunction associated with the virus [42]. The increased expression of CTLA-4 correlates to disease progression markers, and the in vitro blocking of CTLA-4 increases HIV-specific CD4+ T lymphocytes cellular functions [43]. In addition,
Figure 2: Distribution of CD8+ T lymphocyte counts (cells/mL) by the genotypes of the IFNγ (a), IL-6 (b), TNFα (c), IL-10 (d), and TGFβ (e) genes in individuals infected with HIV-1. ns: nonsignificant.

TGFβ may increase the expression of CCR5 and CXCR4, thereby increasing the susceptibility of CD4+ T cells to HIV-1 infection [44].

Thus, our results might suggest that the identification of genetic markers may be required for clinical use and for the stratification of patients into new immunomodulatory treatments. Our results suggest that the predominance of a Th1 over Th2 type response would be ideal to maintain the immune response during HIV-1 pathogenesis and would also influence individual susceptibility to this infection. Our studies suggest that genotypes associated with high levels of IFNγ may contribute to the maintenance of a response by CD4+ T lymphocytes in subjects ART and that the TGFβ suppressor role in the development and maintenance of the
Figure 3: Distribution of HIV-1 plasma viral loads (log₁₀) by the genotypes of the IFNγ (a), IL-6 (b), TNFα (c), IL-10 (d), and TGFβ (e) genes. ns: nonsignificant.
immune response would facilitate viral replication resulting in increased levels of viral load. Thus, future studies analyzing other polymorphisms, gene expression, and serum levels will facilitate mapping and identification of candidate genes for diseases. Moreover, one of the biggest challenges that obstruct the development of vaccines is interindividual variability in the immune response to HIV-1.

In Brazil, little is known about the genetic profiles of cytokines in patients infected with HIV-1 or their influence on disease progression. Therefore, this study contributes to evaluate the frequency of these polymorphisms and their influence on biomarkers of progression of HIV infection in this population. However, additional studies are needed to complement the results presented here to better understand all the mechanisms involved in the progression of infection to AIDS.

Conflict of Interests

The authors declare that they have no conflict of interests.

Acknowledgments

The authors thank all the individuals who participated in the study, as well as the members of LabVir involved in collecting the samples. This work was partially supported by grants from the Brazilian National Council for Scientific and Technological Development (CNPq), the Office of the Dean of Research and Graduate Studies (Pró-Reitoria de Pesquisa e Pós-Graduação (PROPESP/UFPA)), and the Research Support and Development Foundation (Fundação de Apoio e Desenvolvimento da Pesquisa (FADESP)).

References

[1] K. Kedzierska, A. Maerz, T. Warby et al., “Granulocyte-macrophage colony-stimulating factor inhibits HIV-1 replication in monocyte-derived macrophages,” *AIDS*, vol. 14, no. 12, pp. 1739–1748, 2000.

[2] D. Smith, “The long-term consequences of antiretroviral therapy,” *Journal of HIV Therapy*, vol. 11, pp. 24–25, 2006.

[3] G. Panteleo, C. Graziosi, and A. S. Fauci, “Mechanisms of disease: the immunopathogenesis of human immunodeficiency virus infection,” *New England Journal of Medicine*, vol. 328, no. 5, pp. 327–335, 1993.

[4] Z. Bentwich, G. Maartens, D. Torten, A. A. Lal, and R. B. Lal, “Concurrent infections and HIV pathogenesis,” *AIDS*, vol. 14, no. 14, pp. 2071–2081, 2000.

[5] P. An, D. Vlahov, J. B. Margolick et al., “A tumor necrosis factor-α-inducible promoter variant of interferon-γ accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals,” *Journal of Infectious Diseases*, vol. 188, no. 2, pp. 228–231, 2003.

[6] A. Vasilescu, S. C. Heath, R. Ivanova et al., “Genomic analysis of Th1-Th2 cytokine genes in an AIDS cohort: identification of IL-4 and IL-10 haplotypes associated with the disease progression,” *Genes and Immunity*, vol. 4, no. 6, pp. 441–449, 2003.

[7] P. Price, G. Morahan, D. Huang et al., “Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases,” *AIDS*, vol. 16, no. 15, pp. 2043–2047, 2002.

[8] C. A. Dinarello, “Proinflammatory cytokines,” *Chest*, vol. 118, no. 2, pp. 503–508, 2000.

[9] N. L. Michael, “Host genetics and HIV—removing the mask,” *Nature Medicine*, vol. 8, no. 8, pp. 783–785, 2002.

[10] M. Dean, M. Carrington, C. Winkler et al., “Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene,” *Science*, vol. 273, no. 5283, pp. 1856–1862, 1996.

[11] M. Ayres, M. Ayres Jr., D. L. Ayres, and A. S. Santos, *BioEstat 5.0: Aplicações estatísticas nas áreas das ciências biológicas e médicas* [BioEstat 5.0: Statistical Applications in the Areas of Biological and Medical Sciences], Sociedade Civil Mamirauá, Belém, Brazil, 2007.

[12] G. Kaur, C. C. Raphap, N. Kumar, S. Kumar, N. Neola, and N. K. Mehra, “Frequency distribution of cytokine gene polymorphisms in the healthy North Indian population,” *Tissue Antigens*, vol. 69, no. 2, pp. 113–120, 2007.

[13] D. López-Maderuelo, F. Arnalich, R. Serantes et al., “Interferon-γ and interleukin-10 gene polymorphisms in pulmonary tuberculosis,” *The American Journal of Respiratory and Critical Care Medicine*, vol. 167, no. 7, pp. 970–975, 2003.

[14] H. W. Tso, W. K. Ip, W. P. Chong, C. M. Tam, A. K. S. Chiang, and Y. L. Lau, “Association of interferon gamma and interleukin 10 genes with tuberculosis in Hong Kong Chinese,” *Genes and Immunity*, vol. 6, no. 4, pp. 358–363, 2005.

[15] C. Erikstrup, P. Kallestrup, R. B. Ziniyama-Gutsire et al., “Reduced mortality and CD4 cell loss among carriers of the interleukin-10 -1082G allele in a Zimbabwean cohort of HIV-1-infected adults,” *AIDS*, vol. 21, no. 17, pp. 2283–2291, 2007.

[16] S. E. B. dos Santos and J. F. Guerreiro, “The indigenous contribution to the formation of the population of the Brazilian Amazon Region,” *Revista Brasileira de Genetica*, vol. 18, no. 2, pp. 311–315, 1995.

[17] C. Wang, W. Song, E. Lobashevsky et al., “Cytokine and chemokine gene polymorphisms among ethnically diverse northamericans with HIV-1 infection,” *Journal of Acquired Immune Deficiency Syndromes*, vol. 35, no. 5, pp. 446–454, 2004.

[18] S. Veloso, M. Olona, F. García et al., “Effect of TNF-α genetic variants and CCR5Δ32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards,” *BMC Medical Genetics*, vol. 11, no. 1, article 63, 2010.

[19] B. Maher, A. Alfirevic, F. Javier Vilar, E. G. L. Wilkins, B. K. Park, and M. Pirmohamed, “TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy,” *AIDS*, vol. 16, no. 15, pp. 2013–2018, 2002.

[20] M. W. Quasney, Q. Zhang, S. Sargent, M. Mynatt, J. Glass, and J. McArthur, “Increased frequency of the tumor necrosis factor-α-308 A allele in adults with human immunodeficiency virus dementia,” *Annals of Neurology*, vol. 50, no. 2, pp. 157–162, 2001.

[21] H. L.-Wong, E. C. Breen, R. M. Pfitzner et al., “Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study,” *AIDS*, vol. 24, no. 7, pp. 1025–1033, 2010.

[22] D. D. Naicker, B. Wang, E. Losina et al., “Association of IL-10-promoter genetic variants with the rate of CD4 T-cell loss, IL-10 plasma levels, and breadth of cytotoxic T-cell lymphocyte response during chronic HIV-1 infection,” *Clinical Infectious Diseases*, vol. 54, no. 2, pp. 294–302, 2012.
[23] D. D. Naicker, L. Werner, E. Kormuth et al., “Interleukin-10 promoter polymorphisms influence HIV-1 susceptibility and primary HIV-1 pathogenesis,” Journal of Infectious Diseases, vol. 200, no. 3, pp. 448–452, 2009.

[24] S. Shrestha, H. W. Wiener, B. Aissani et al., “Interleukin-10 (IL-10) pathway: genetic variants and outcomes of HIV-1 infection in African American adolescents,” PLoS ONE, vol. 5, no. 10, Article ID e13384, 2010.

[25] N. H. S. Deghaide, M. D. L. V. Rodrigues, E. C. Castelli, C. T. Mendes Jr., J. F. C. Figueiredo, and E. A. Donadi, “Tumor necrosis factor region polymorphisms are associated with AIDS and with cytomegalovirus retinitis,” AIDS, vol. 23, no. 13, pp. 1641–1647, 2009.

[26] L. Castelar, M. M. Silva, E. C. Castelli et al., “Interleukin-18 and interferon-gamma polymorphisms in Brazilian human immunodeficiency virus-1-infected patients presenting with lipodystrophy syndrome,” Tissue Antigens, vol. 76, no. 2, pp. 126–130, 2010.

[27] R. C. Sobti, A. M. Salih, B. Nega et al., “Insights into the role of IL-12B and IFN-γ cytokine gene polymorphisms in HIV-1/AIDS infection,” Folia Biologica, vol. 56, no. 3, pp. 110–115, 2010.

[28] M.-W. Kang, C.-W. Pyo, S.-H. Wie et al., “Associations of IFN-γ polymorphism with HIV-1 infection in the Korean population,” AIDS Research and Human Retroviruses, vol. 22, no. 3, pp. 297–299, 2006.

[29] M. Izad, M. Vodjgani, M. H. Nicknam, J. Lotfi, D. Fathi, and S. Shrestha, H. W. Wiener, B. Aissani et al., “Interleukin-10 (IL-10) pathway: genetic variants and outcomes of HIV-1 infection in African American adolescents,” Journal of Infectious Diseases, vol. 200, no. 3, pp. 448–452, 2009.

[30] R. T. Bailer, A. Holloway, J. Sun et al., “IL-13 and IFN-γ secretion by activated T cells in HIV-1 infection associated with viral suppression and a lack of disease progression,” Journal of Leukocyte Biology, vol. 88, no. 2, pp. 303–311, 2010.

[31] G. C. Blobe, W. P. Schiemann, and H. F. Lodish, “Role of transforming growth factor β in human disease,” The New England Journal of Medicine, vol. 342, no. 18, pp. 1350–1358, 2000.

[32] J. Andersson, A. Boasso, J. Nilsson et al., “Cutting edge: the prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients,” Journal of Immunology, vol. 174, no. 6, pp. 3143–3147, 2005.

[33] D. E. Kaufmann, D. G. Kavanagh, F. Pereyra et al., “Upregulation of CD4+ by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction,” Nature Immunology, vol. 8, no. 11, pp. 1246–1254, 2007.

[34] J. L. Riley, K. Schlenger, P. J. Blair et al., “Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule,” Journal of Experimental Medicine, vol. 191, no. 11, pp. 1987–1997, 2000.